HIPRA receives European Commission approval for the commercialisation of its COVID-19 vaccine adapted to the LP.8.1 variant
The demonstration of the vaccine's efficacy in its preclinical phase was carried out at the Comparative Medicine and Bioimage Centre of Catalonia, a trategic project of IGTP.
